

# The use of induced pluripotent stem cell-derived cardiomyocytes to study cardiac arrhythmias and cardiomyopathies

Created on: 03-06-2020 - Last modified on: 30-06-2020

#### **Contact person**

Maaike Alaerts

#### Organisation

Name of the organisation University of Antwerp (UAntwerpen) Department Center of Medical Genetics Country Belgium Geographical Area Flemish Region

## SCOPE OF THE METHOD

The Method relates to	Human health
The Method is situated in	Basic Research, Translational - Applied Research
Type of method	In vitro - Ex vivo
Specify the type of cells/tissues/organs	Induced pluripotent stem cell-derived cardiomyocytes

## DESCRIPTION

#### Method keywords

induced pluripotent stem cells Disease modeling Cardiomyocyte drug screening CRISPR/Cas

#### Scientific area keywords

cardiac arrhythmia cardiomyopathy Brugada syndrome

#### **Method description**

Cardiomyocytes derived from induced pluripotent stem cells (iPSC-CMs) offer an attractive platform for cardiovascular research, including disease modeling, drug toxicity testing and development of regenerative therapies. Patient-specific iPSC-CMs are very useful to study disease pathogenesis and have a huge potential for evaluation of disease prognosis and development of personalized treatment. In our research group we study inherited cardiac arrhythmias (currently with a focus on Brugada syndrome) and

cardiomyopathies. We create iPSC-CM models, either patient-derived or using CRISPR/Cas, to evaluate the functional effect of specific genetic variants, assist the search for modifier genes and novel therapeutic targets, and screen for novel drug compounds.

## Lab equipment

- Biosafety cabinets ;
- Nucleofector ;
- Patch-clamp equipment ;
- Multi-electrode array (MEA) ;
- Next-generation sequencing (NGS) instruments.

## Method status

Still in development Internally validated

# **PROS, CONS & FUTURE POTENTIAL**

#### Advantages

Human model mimicking the native cardiomyocyte environment, patient-based disease model recapitulating full genomic background.

#### Challenges

Relative immaturity of the cells, variability of the phenotype of the final iPSC-CM model

#### Modifications

Improved protocols for more standardized differentiation and maturation of the cardiomyocytes.

## Future & Other applications

iPSC-CMs can as well be used for drug cardiotoxicity screening and regenerative therapies after further improvements and validation.

## **REFERENCES, ASSOCIATED DOCUMENTS AND OTHER INFORMATION**

Coordinated by









